Three patients enrolled in a Phase I safety trial each received a virus injected directly into their pancreatic tumors. All three remained alive with stable disease after treatment. One of them has now held that stability for a full year. The dose given was one-tenth of what researchers are ultimately aiming for.
Pancreatic cancer is the third leading cause of cancer-related deaths in the United States, and its five-year survival rate sits at just 13% as of January 2026. The biology of the disease explains why that number moves so slowly despite decades of research. Pancreatic cancer is often diagnosed after the disease has advanced, and its dense, fibrous tumors can limit the effectiveness of existing therapies. Only about 15 to 20 percent of all pancreatic tumors are resectable – meaning surgically removable – at the time of diagnosis.
Chemotherapy can modestly extend survival in patients with unresectable disease, but the field has been searching for a fundamentally different approach. The investigational viral therapy now being tested in Minneapolis is among the more closely watched candidates in current pancreatic cancer research.
How Viral Therapy for Pancreatic Cancer Works
Research led by Masato Yamamoto, MD, an investigator at the Masonic Cancer Center, University of Minnesota, has drawn international attention following coverage in New Scientist on an early-phase clinical trial of an engineered oncolytic adenovirus for pancreatic cancer. In its natural form, an adenovirus causes common cold and flu-like illnesses. Yamamoto’s team has genetically rebuilt one to target cancer cells specifically.
Oncolytic viruses are naturally occurring or genetically engineered viruses that selectively target and destroy cancer cells through mechanisms including direct tumor cell lysis, stimulation of immune-mediated cytotoxicity, and modulation of the tumor microenvironment. The version Yamamoto’s team developed uses a cyclooxygenase-2, or COX-2, promoter to drive viral replication selectively inside cancer cells. COX-2 is an enzyme that is overexpressed in pancreatic cancer cells, making it a precise molecular target for a therapy designed to leave healthy cells alone.
Once the virus enters a tumor cell, it begins to copy itself. Oncolytic adenoviruses replicate inside tumor cells, eventually lysing – or bursting – them apart. The dead cell releases more viral particles, which then infect neighboring cancer cells and repeat the process. Healthy tissue, lacking the COX-2 overexpression that acts as the virus’s replication signal, is bypassed.
The delivery mechanism adds another layer of precision. Endoscopic ultrasound – a minimally invasive procedure that threads a camera and needle through the digestive tract – provides real-time imaging and allows direct injection of the therapeutic virus into the tumor itself. The pancreas sits deep in the abdomen, surrounded by major blood vessels, and is not easily accessible through conventional surgical routes.
What the Early Results Actually Show
The Phase I study, presented at the American Society of Gene and Cell Therapy Annual Meeting, is evaluating the safety of the investigational therapy in patients with locally advanced pancreatic cancer – where the disease has spread beyond the pancreas into nearby tissues but not to distant organs. All three participants in the first cohort remained in stable disease following treatment.
“They are all still alive and have clinically stable disease,” Yamamoto said when presenting the results at the annual meeting in Boston. Stable disease in locally advanced pancreatic cancer, particularly for patients with limited remaining options, represents a meaningful clinical outcome in a setting where progression is the typical trajectory.
Those first patients received the engineered virus at one-tenth of the dose researchers ultimately intend to use, yet the therapy produced tumor stabilization at that level. The trial is now moving forward with higher doses, and researchers are monitoring closely to see whether a stronger viral load produces deeper tumor responses or, in some patients, regression.
Why Pancreatic Tumors Are So Hard to Treat
Pancreatic tumors have tough, fibrous exteriors that physically block chemotherapy drugs from penetrating the tumor mass. This structural barrier, called the desmoplastic stroma, is one of the main reasons even potent drug combinations fail to reach cancerous cells in adequate concentrations. An oncolytic virus, replicating and spreading from cell to cell inside the tumor, is not obstructed by the same barrier.
The high aggressiveness of pancreatic cancer is attributed to factors including late diagnosis, an immunosuppressive and desmoplastic tumor microenvironment, early metastasis, and resistance to conventional therapies. Novel immunotherapies such as immune checkpoint inhibitors have also shown limited efficacy in clinical trials for pancreatic cancer. Checkpoint inhibitors – drugs that release the immune system’s brakes so it can attack tumors – have transformed survival rates in melanoma, lung cancer, and other solid tumors, but pancreatic cancer has remained largely resistant to them.
The resistance relates to immune activity inside the tumor. Pancreatic cancer is classified as an immunologically “cold” tumor, meaning it has insufficient T-cell infiltration and low expression of the immune proteins that checkpoint drugs require to function. Without that immune activity already present, checkpoint inhibitors have little to work with.
Oncolytic viruses induce a lytic form of cell death that is highly immunogenic, with the potential to activate immune responses inside otherwise cold tumors. When tumor cells burst from viral replication, they release molecular signals that attract immune cells to the site, prompting the immune system to begin recognizing the tumor as a threat.
Combining Viruses with Immunotherapy
Yamamoto and his colleagues are planning to combine the viral treatment with immune checkpoint inhibitors in future clinical trials. Oncolytic viruses that can activate the tumor microenvironment and draw T-cells in may give checkpoint inhibitors the immune-active terrain they need to function effectively in pancreatic cancer.
Beyond their direct tumor-killing activity, oncolytic viruses influence the immune environment by modulating the PD-1/PD-L1 axis, a key pathway in cancer immune evasion. Early evidence suggests the combination of oncolytic viruses and checkpoint inhibitors may be synergistic – the virus priming an immune response that checkpoint drugs can then amplify.
A separate line of research has yielded daraxonrasib, a KRAS-targeting drug that received FDA Breakthrough Therapy Designation for previously treated metastatic pancreatic ductal adenocarcinoma with KRAS G12 mutations. Viral therapy and targeted drugs approach the disease through different mechanisms, and researchers are beginning to ask whether combining them could produce results neither achieves alone.
What This Means for You
This trial remains in its earliest phase. Phase I studies are designed primarily to assess safety and establish dosing – they are not powered to prove that a treatment works across a broader patient population. The three patients with stable disease are a real, encouraging signal, not a confirmed treatment breakthrough. Patients with pancreatic cancer or a family member with a recent diagnosis can find information about ongoing trials, including those at the Masonic Cancer Center, through ClinicalTrials.gov.
The mechanism behind this viral therapy addresses three core problems in pancreatic oncology simultaneously: the fibrous barrier that blocks drugs, the cold immune environment that blunts immunotherapy, and the late-stage diagnosis that leaves patients with few surgical options. Adenoviruses have been investigated as potential cancer treatments for decades, but modern genetic engineering has produced far more precise instruments than early researchers had access to.
Yamamoto’s team is building on that refinement, and the COX-2 targeting mechanism represents a specific design choice aimed at the biological weakness that makes pancreatic tumors so dangerous. The next phase of the trial, at higher doses and with more patients, will determine whether that targeting holds at therapeutic levels.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: The Pancreatic Cancer Pill That Made Oncologists Stand Up and Cheer
